Dogwood Therapeutics (NASDAQ:DWTX) Earns Buy Rating from HC Wainwright

Dogwood Therapeutics (NASDAQ:DWTX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 309.56% from the company’s previous close.

A number of other equities analysts have also weighed in on DWTX. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Dogwood Therapeutics presently has an average rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Price Performance

Shares of Dogwood Therapeutics stock opened at $2.93 on Friday. The firm has a market cap of $6.71 million, a PE ratio of -0.12 and a beta of 1.88. Dogwood Therapeutics has a 1 year low of $2.60 and a 1 year high of $14.69. The stock has a fifty day moving average price of $3.62 and a 200-day moving average price of $4.93.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. 9.05% of the stock is owned by hedge funds and other institutional investors.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.